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1.1 Urinary Tract Infections 
Urinary tract infections (UTIs) affect approximately 150 million people per year 
worldwide and account for more than 10 million outpatient and emergency room visits in the 
United States alone1,2. More than 3 billion dollars are spent annually in the U.S. for sick leave 
and treatment of these patients, the majority of whom are women1,3,4. The anatomy of women 
puts them at higher risk of developing a urinary tract infection than men for two reasons. The 
female urethra is positioned closer to the vagina and anus where bacteria are in high abundance 
which facilitates the translocation of bacteria to the periurethral region5,6. Additionally, the 
female urethra is shorter than male, which aids bacteria entry into the bladder6. More than 50% 
of women will experience a UTI in their lifetime and of those who do, 25% are likely to suffer 
from a second infection within 6 months7–9. 
Recurrent UTIs (rUTIs) following initial infections are likely attributed to a weak host 
adaptive immune response to the uropathogen causing infection although research has 
demonstrated that a strong response can be formed9,10. Weak responses may result from early 
childhood exposure to a uropathogen or maternal history of UTI9,11. While most acute urinary 
tract infections can be resolved with antibiotics, increased antibiotic resistance to uropathogens 
has made treatment of rUTI challenging9. Recurrent infections risk developing into a chronic 
infection that can persist for months despite treatment9.  
UTIs are classified into two categories: uncomplicated and complicated. An 
uncomplicated UTI occurs in an otherwise healthy individual and is effectively treated with a 
course of antibiotics. A complicated UTI often occurs in patients with catheters, urinary 






infection include prior UTIs, sexual activity, vaginal infection, diabetes, obesity, and genetic 
predisposition12,13. 
1.2 Uropathogenic Escherichia coli 
While UTIs can be caused by many types of bacteria and fungi, the primary culprit is 
uropathogenic Escherichia coli (UPEC), a gram negative bacteria responsible for more than 75% 
of community-acquired and 50% of nosocomial infections1,14. Microbiome studies measuring 
UPEC in healthy stool show that these strains are often commensal to the gut, but once shed, can 
migrate from fecal material to colonize the vaginal and periurethral regions15. In the urethra, 
UPEC becomes pathogenic and upregulates production of multiple virulence factors like toxins, 
adhesins and proteases to ascend into the bladder16. These factors help bacteria bind and invade 
bladder epithelial cells within the first few hours of arrival as shown in mouse models of UTI17. 
Invading these cells allows UPEC to hide from the host immune system while replicating8. 
Severe infections can further ascend into the kidneys where they become complicated to treat. 
Untreated, pyelonephritis can be fatal as bacteria may escape into the bloodstream causing 
bacteremia and sepsis4.  
One way UPEC increases its virulence is by upregulating expression of surface adhesion 
molecules like type 1 pili, which is essential for invasion of the luminal facet epithelial cells of 
the bladder18. In fact, one study showed type 1 pili to be expressed in 95% of isolates from 
urinary tract infections19. Once inside the cell, UPEC replicates within the cytoplasm to form 
intracellular bacterial communities (IBCs) that make a biofilm-like structure and can be 
visualized by microscopy20. IBC formation is an important part of UPEC pathogenesis as studies 






bladder21. After 12-16 hours of infection, these formations take on a filamentous structure to flux 
out of epithelial cells into the lumen of the bladder8. This new arrangement can deposit bacteria 
on neighboring bladder cells to advance the infection and is too large to be engulfed by 
neutrophils8,9,22. In an attempt to clear the infection, compromised superficial epithelial cells 
undergo a process similar to apoptosis and are exfoliated into the urine to be excreted9,23. 
Rather than incorporating into the filamentous structure, some UPEC escape to endocytic 
vesicles located within transitional cells deeper in the urothelium where they form quiescent 
intracellular reservoirs (QIRs). Containing up to 15 inactive bacteria, these reservoirs can exist 
for months without shedding bacteria into the urine, making them undetectable to the host 
immune system8,9,20,24. Additionally, QIRs are resistant to 3 and 10 day courses of antibiotics, 
making them difficult to destroy20. Though normally dormant, QIRs can revert to an active state 
during epithelial cell turnover to cause a recurrent infection8,9,22,24. Their resiliency increases the 
difficulty of identifying and resolving UTIs.  
1.3 Diagnosis and Treatment of UTI 
1.3.1 Diagnosis 
A UTI is suspected when a patient presents with symptoms of burning, urgency, and 
frequency of urination. These symptoms may be accompanied by fever, chills, hematuria, 
bladder spasms, and pelvic or back pain; the latter suggests pyelonephritis.  
Diagnosis of a UTI involves culturing bacteria from a clean-catch urine specimen25. The 
result of the culture is used to calculate the colony forming units per ml (CFU/ml) and defines a 
positive result as 105 CFU/ml or higher25. This technique, first developed in the 1950’s, has been 






research groups for its limitations in culturing slow-growing microbes, lack of selectivity, and 
inability to detect less than 103 CFU/ml5,26,27. A more sensitive method, expanded quantitative 
urine culture (EQUC), uses larger sample input, anaerobic conditions, and multiple media types 
to grow a variety of bacteria26. Upon comparison, EQUC has exposed the current method to have 
a 90% false negative rate5,26. Some caveats to this method are its use of more specialized and 
expensive equipment, along with slower results due to longer incubations.  
Up to 20% of women who have physical symptoms of a UTI do not meet the diagnostic 
cutoff by culture, so alternate methods can help identify whether an infection is present28. Other 
common diagnostic methods include the dipstick test which measures nitrite, protein, leukocyte 
esterase, and blood in the urine. While this information is somewhat helpful, results from a 
dipstick test alone tend to have a high false positive rate and can lead to inappropriate antibiotic 
usage25. Microscopy and immersion culture media can also be used, but these methods only 
slightly improve diagnostic accuracy25. The lack of reliable diagnostic testing leaves room for the 
development of other biomarkers of urinary tract infections to help in cases that do not meet the 
current diagnostic standards.  
1.3.2 Treatment 
Most urinary tract infections are treated with a single course of antibiotics25. Appropriate 
antibiotic selection has become increasingly important not only because of the marked increase 
in antibiotic resistant organisms, but also due to the development of allergies in repeatedly 
exposed patients, a majority of whom are women28,29. Therefore, alternative treatments are 
currently under development. One study shows promising results for the oral administration of 






urine13. Another treatment currently in clinical trials involves vaccination against UPEC adhesins 
that are essential for infection. The vaccination is designed to use the body’s immune system to 
help remove UPEC from the reservoir in the gut thereby reducing the likelihood of a UTI30,31.  
Treatment becomes more challenging when a patient experiences frequent and recurrent 
UTIs (rUTI). Often a long-term, prophylactic antibiotic treatment is employed, and although 
effective, can result in pathogen resistance and allergic reactions in the host32–34. In extreme 
cases, surgical removal of the bladder is performed to break the cycle of recurrence35. 
Other conditions may be misdiagnosed as a UTI and lead to unnecessary antibiotic 
treatment. This occurs in part due to the overlap in symptomatology as sexually transmitted 
infections (STIs) can also cause dysuria, frequency and urgency36. Studies in the emergency 
department have shown more than 50% of diagnosed UTIs return a negative culture of which 
almost 20% test positive for an STI36,37. Overactive bladder syndrome along with myofascial 
pain of the pelvic floor can also be misinterpreted as UTIs38,39. Possibility of STI and other 
urologic conditions should be considered during the patient examination, especially in cases 
returning negative cultures and failure of prior antibiotic treatment.  
1.4 Asymptomatic bacteriuria 
While some urine samples do not meet the diagnostic cutoff, patients with asymptomatic 
bacteriuria (ABU) often surpass this threshold. ABU is diagnosed by two consecutive, positive 
clean-catch urine cultures in the absence of signs or symptoms of infection40,41. While the 
incidence rate of ABU increases with age, a higher proportion of cases continue to be in 
females40. This rate is 1-5% in healthy premenopausal women and increases to 40% in female 






understood, some evidence suggests the host response is weaker in ABU patients possibly 
reflecting genetic differences in innate immune mediators40. A urine proteome analysis revealed 
significantly increased levels of immune markers including neutrophils, IL-8 and GRO-α, a 
neutrophil attractant molecule, compared to urine from healthy controls41. This finding 
demonstrates that ABU patients may still have elevated immune marker levels typical of UTIs 
without experiencing any symptoms of infection. Increased immune markers along with a 
positive culture result could easily be misclassified as a urinary tract infection.  
As in UTIs, more than one species of bacteria can contribute to ABU, but E. coli is most 
frequently cultured from patient urine samples1,27,40,41. A urine culture analysis of acute 
pyelonephritis samples showed a higher occurrence of type 1 pili expressing E. coli serotypes 
compared to samples from patients with ABU14,42. This data suggests that presence of bacteria in 
the urine may not be problematic in some cases. In fact, the presence of bacteria in ABU patients 
is thought to be protective against colonization of pathogenic bacteria that may cause 
infections43. Since this discovery, clinicians have been advised not to treat a majority of these 
cases43.  Use of antibiotics in ABU patients has not only led to multidrug resistant bacteria, but 
also increased rates of urinary tract infections43. Distinguishing ABU and UTI cases has been 
challenging and development of other markers of infection is needed to aid in this effort. 
1.5 Urinary microbiome 
The central dogma of UTI research postulates that healthy urine is sterile44,45. However, 
discovery of bacterial DNA and live bacteria in the urine of women lacking UTI symptoms 
suggests the existence of a urinary microbiome27,44,45. Using expanded quantitative urine culture 






the colon which is inhabited by approximately 1011 CFU/g44. The urinary microbiome is also less 
diverse than that of the gut and more on par with the microbiome of the eye44. Similar to 
microbiomes found in other regions of the body, the microbial community found in the bladder 
may protect against invading pathogens44,45. Across multiple studies of the urinary microbiome, 
Lactobacillus species tend to be higher in healthy control groups27,44,45. This genera has been 
well established as a healthy commensal in the neighboring vaginal microbiome45,46.  
The difficulty in exploring the urinary microbiome exists in the methodology. As 
discussed previously, current culturing methods are limited in sensitivity and selectivity. The 
development of more sensitive techniques like 16S rRNA gene sequencing and advanced 
culturing methods allowed detection of low abundance microbes, and provided compelling 
evidence that a urinary microbiome exists26. Pearce et al. performed a urinary microbiome study 
on women with and without urgency urinary incontinence (UUI)44. Urine samples were collected 
by transurethral catheterization and analyzed using 16S rRNA sequencing and EQUC. 
Sequencing showed the cohorts had equal amounts of bacterial DNA, and were largely 
composed of one or two genera, usually Lactobacillus or Gardnerella. Additionally, compared to 
EQUC, they show the standard culturing method has a 90% false negative rate across both 
cohorts. Results from EQUC and 16S rRNA sequencing revealed that both methods classify 
more than half of all samples positive for bacteria. To deconvolute the study, subjects with a 
history or current UTI were excluded, as these conditions are likely to disrupt the microbial 
community.  
A major source of speculation in these studies is the likelihood of contamination by 
vaginal or gut flora during urine collection27. To determine the method with minimal 






catheterization and suprapubic aspiration27. Overall, bacterial composition was similar among the 
three techniques, with the most taxonomic overlap in catheterization and aspiration27. Voided 
urine tends to have the most vaginal contamination, although catheterization can also introduce 
microbes into the bladder45. The collection method chosen will need to be carefully considered 
when evaluating a study and improvement in technology will help distinguish contaminants, 
bladder commensals, and uropathogens.    
1.6 Host immune response to UTI 
The host immune system has a multifaceted response to a UTI. First, the innate immune 
response takes nonspecific action against pathogens through the use of pattern recognition 
receptors (PRRs)47. These receptors are expressed on the surface of epithelial and immune cells 
to recognize specific pathogen-associated molecular patterns (PAMPs) or danger/damage 
associated molecular patterns (DAMPs)47. Once a signal is detected, the cell creates a 
multiprotein complex, the inflammasome, to organize production and secretion of inflammatory 
molecules into the extracellular environment35. This will also signal defensins, alarmins, and 
other antimicrobial proteins to be upregulated48.  
Antimicrobial peptides (AMPs) are one of the first host defenses to take action against a 
urinary tract infection49. They are usually small, positively charged proteins produced by 
epithelial cells and neutrophils that can be constitutively expressed or induced by bacterial 
stimuli49. Close association with bacterial membranes is believed to be one way in which they 
exhibit bactericidal effects49,50. Bacteria express a variety of negatively charged proteins on the 
cell surface that may bind cationic AMPs49. Some AMPs use special structures to bore into 






contents and eventually kill the pathogen52. Defensins are the most well studied AMPs in the 
urinary tract and are increased during infection52. Neutrophils produce 4 types of α-defensins that 
employ non-oxidative antimicrobial activity and were increased in patients with chronic 
pyelonephritis53. Cathelicidin is another AMP expressed by epithelial cells that, in vitro, 
increases in mRNA transcripts within 5-15 minutes of contact with bacteria54,55. Since their 
discovery, these molecules have been explored as therapeutics in UTI, however they have a short 
lifespan and cannot compete with antibiotics49. 
One of the PRRs involved in activating the innate immune response against UPEC is 
Toll-like receptor 4 (TLR4). TLR4 expressed on macrophages recognizes lipopolysaccharide 
(LPS) found on gram negative bacteria including UPEC56. Once LPS binds TLR4, a signaling 
cascade will activate the NFκB pathway to upregulate transcription of inflammatory cytokines 
including IL-1β, IL-6, and TNFα in addition to chemotactic molecules IL-8 (MIP-2 murine 
homolog) and G-CSF which attracts and stimulates expansion of granulocytes9,57,58. This 
increase in cytokines occurs within 1 hour of bladder inoculation and peaks at 24 hours post 
infection (hpi)48,58. Accumulation of proinflammatory cytokines creates the  environment needed 
to activate and recruit neutrophils to the site of infection58. Upon exiting circulation, neutrophils 
migrate through the urothelium, arrive in the lumen of the bladder within 2 hours and peak in 
concentration at 24 hpi59,60. Neutrophils kill bacteria by engulfment, degranulation and release of 
extracellular traps (NETs)50,59. These cells are thought to be the pinnacle innate cell type to 
combat bacterial colonization in the bladder58–60. However, neutralization of G-CSF reduces the 
number of neutrophils in circulation and therefore recruitment, which surprisingly leads to 
decreased bacterial burden58. G-CSF is specific to neutrophils but not their monocyte precursor; 






Monocytes may also work in conjunction with resident macrophages to increase expression of 
enzymatic matrix metalloproteinase 9 (MMP-9) production in neutrophils61. MMP-9 breaks 
down collagen to aid neutrophil migration to the lumen of the bladder10,61. Some evidence 
suggests that mast cell production of IL-10, an anti-inflammatory cytokine, also plays a crucial 
role in balancing the inflammatory environment in UTI9. Additional in vitro studies found mast 
cell products, including TNFα, induce activation of NFκB in bladder epithelial cells62. Mice 
deficient in mast cell production had higher UPEC titers in the bladder following infection63. 
Another facet of the innate immune response of the bladder involves γδ T cells which kill 
infected epithelial cells through secretion of granzymes64. γδ T cell knockout mice have higher 
bacterial burden suggesting that although small in number, these cells play a significant role in 
fighting UTI64. In fact, elevated levels of these cells in the lamina propria of naive mice improve 
host defense against UTI9.   They are also a major source of IL-17A in the infected bladder, 
suggesting they may activate recruited T cells at the site of infection64.  
Although most studies have focused on the innate immune system response to UTI, 
several groups have investigated the role of the adaptive immune system. Importantly, since the 
high rate of recurrence in UTI is thought to be because of a weakened adaptive immune 
response, it deserves further inquiry61. Two cytokines associated with recruitment and activation 
of T cells, RANTES and IL-12 p40, are increased in mice 48 hpi58. Furthermore, transfer of T 
cells from infected mice to naive ones diminishes UPEC colonization upon challenge65. One 
group discovered that macrophages play a major role in the beginning of adaptive immunity by 
taking up bacteria soon after inoculation of the bladder61. Depletion of resident macrophages in 
infected mice leads to improved adaptive immune responses. While initially a puzzling result, it 






immune response61. Depleting macrophages allowed a 2 fold increase in antigen presented by 
dendritic cells and led to a more robust adaptive immune response61.   
1.7 Secretory leukocyte protease inhibitor 
Secretory leukocyte protease inhibitor (SLPI) is an innate antimicrobial peptide expressed 
at mucosal surfaces including the bladder, but little is known about its effect on urinary tract 
infection57,66,67 (Figure 1.1). SLPI is one of 18 proteins in the whey acidic protein (WAP) family, 
only a few of which have been characterized past the gene level68. A defining characteristic of 
this family is the prevalence of intramolecular disulfide bonds. SLPI, a 12 kD cationic protein 
with 107 amino acids, contains 8 of these bonds connecting its two domains: C and N68. The C 
domain functions as an inhibitor of serine proteases while the N domain is associated with 
antimicrobial activity68. Interestingly, these functions appear to be independent as truncated SLPI 
to include only the C or N terminal allows it to retain antiprotease or antimicrobial function 
respectively69–71. Although, comparatively, intact SLPI is more efficient69. Furthermore, even 
when covalently bound to the extracellular matrix physically blocking it from damage, SLPI still 
preserves its antiprotease activity72. 
1.7.1 Functions of SLPI 
Antiprotease function of SLPI against serine proteases has been well established. At the 
site of inflammation, recruited neutrophils and activated mast cells release serine proteases: 
neutrophil elastase (NE), cathepsin G, chymase and tryptase, to increase local inflammation50. 






expressed in the gut73. Crystallization of SLPI complexed to NE has allowed further examination 
of this interaction74. This complex increases in inflamed states of the lung and skin75,76.  
Originally discovered for its antiprotease activity, SLPI was found to also function as an 
antimicrobial demonstrating activity against gram positive and negative bacteria, fungi, protozoa 
and viruses. Not only does SLPI kill bacteria in culture as shown with Escherichria coli and 
Staphylococcus aureus, but a cell free system also suggests that it can bind bacterial mRNA and 
DNA to prevent protein synthesis14,69. SLPI is also shown to directly bind Neisseria gonorrhoeae 
Opa protein expressed on the surface of bacteria77. In addition to bacteria, cell culture assays 
show SLPI to associate with Candida albicans, a major cause of vaginal yeast infections, to 
prevent invasion of vaginal epithelial cells78. Moreover, infection of Slpi-/- mice with Leishmania 
major showed increased parasite burden in Slpi-/- both at the site of injection and distal organs 
showing the infection becomes systemic without SLPI onboard79. A large amount of research has 
investigated the role of SLPI in HIV infection and found it reduces perinatal transmission by 
competitively binding annexin A2 (AnxA2) to block viral invasion of macrophages80. This cell 
surface receptor, AnxA2, is also expressed on bladder epithelium and may prevent UPEC 
expressing Yad fimbriae from invading the urothelium81.  
Some microbes have developed mechanisms to combat the bactericidal effects of SLPI. 
Pseudomonas aeruginosa can secrete pseudolysin, a specialized protease that cleaves SLPI82,83. 
Additionally, a gastrointestinal cell line infected with Helicobacter pylorii also demonstrates the 
ability to cleave SLPI84. This could explain why biopsies from patients with H. pylorii-induced 
gastritis have low levels of SLPI secretion in the antrum85.  
SLPI is also known to modulate inflammation and there are multiple hypotheses on the 






as shown in a guinea pig model of allergic conjunctivitis in which topically applied SLPI 
reduced eosinophil recruitment in infected animals86. Other data supports the hypothesis that 
SLPI can modulate activity of activated immune cells. One study showed SLPI can prevent 
secretion of histamine from IgE-activated mast cells in the lung87. Inside monocytes, SLPI can 
inhibit synthesis of MMP9, a protease that aids neutrophil migration through tissue88. 
Furthermore, neutrophil phagocytosis, oxidative burst and NETosis can also be inhibited by 
SLPI80,89. The third hypothesis is also the one most studied: SLPI inhibits the NFκB pathway to 
reduce inflammation. This direct inhibition has been demonstrated in vitro to show SLPI can be 
taken up by monocytes and activated macrophages90. Once inside the cell, SLPI translocates to 
the nucleus to bind NFκB promoter regions of inflammatory cytokines thus preventing their 
transcription to decrease inflammation90. Macrophages and monocytes are known to produce and 
secrete SLPI, but whether or not it can be taken up in vivo is still unclear. SLPI may inhibit 
NFκB indirectly by preventing degradation of NFκB inhibitors IkBα and IkBβ 90.  
1.7.2 Expression and regulation of SLPI 
SLPI is constitutively expressed in mucosal tissue of the respiratory, gut and urogenital 
tracts and is secreted by epithelial cells, neutrophils and macrophages into mucosal fluids 
including saliva, nasal mucus, vaginal secretions and urine50,66. SLPI production is stimulated by 
microbial products LPS and viral RNA91,92. Colonization of germ-free mice confirmed SLPI is 
upregulated in gut epithelial cells upon contact with bacteria, implying exposure to microbes and 
their products can induce production of SLPI93. In addition to PAMPs upregulating SLPI, a 






IL-1β, IL6 and TSLP73,91,94–96. In return, SLPI can induce macrophages to secrete TGFB and IL-
10 to reduce inflammation97.  
Estrogen increases production of AMPs including SLPI98–101. In women, SLPI and 
estrogen levels are highest during the ovulatory stage98. Indeed, cell culture assays confirm 
incubation of vaginal epithelial cells with estrogen increases SLPI production99. Post-
menopausal women have low levels of estrogen which can increase risk of developing rUTI102. 
Vaginal application of oestrogen has reduced frequency rUTI22. Estrogen also reduces epithelial 
cell exfoliation100. Taken together, the reduction in urothelium cell turnover and increased 
concentrations of AMPs may act to prevent QIR activation and therefore their contribution to 
rUTIs100,101,103.  
1.7.3 SLPI in mouse models of disease 
SLPI has been studied in a variety of diseases. The similarity in structure of human and 
murine slpi has made mouse models a promising technique for the study of SLPI in disease states 
relevant to humans104. Development of a Slpi-/- mouse has aided understanding of the specific 
role this protein has in vivo96.   
Three models in which SLPI has been studied include wound healing, airway 
inflammation and lower reproductive tract infections. Since the discovery of SLPI in saliva in the 
1980’s, a large amount of research has been dedicated to the study of SLPI in airway 
conditions105. In the lung, SLPI is found in high abundance in part due to its sensitivity to 
oxidation from having multiple methionine residues50,82. Meaning, a large amount of SLPI may 
be required to maintain homeostatic levels. Being highly expressed in the lung led to research on 






that worsen disease. Tested as a possible therapeutic, SLPI was aerosolized into the lungs of 
these patients and reduced NE and CXCL8, a neutrophil chemoattractant106. However, it was 
unable to reach more diseased areas of the lung and has since been abandoned106. In COPD and 
asthma, studies have found lower levels of SLPI in diseased patients compared to controls107,108. 
An ovalbumin mouse model of allergic airway inflammation (AAI), reported Slpi-/- mice have 
increased eosinophil infiltration, goblet cells hyperplasia and worsened lung function91. Using 
this model, another study showed SLPI to modulate airway microbiota108. 
SLPI is upregulated in human cutaneous wounds and improves healing by inhibiting host 
proteases and regulating inflammation76. A group studying wound healing introduced a Slpi-/- 
mouse line to study the specific effects SLPI has on chronic wounds96. Wounded Slpi-/- mice 
have reduced rates of clotting and healing as well as increased levels of TNFα, neutrophils and 
NE96. Activated neutrophils secrete NE which, in excess, can be detrimental to host tissue50,61. 
SLPI inhibiting NE improves wound healing in two ways: reduces host tissue damage and 
prevents cleavage of proepthilin, a growth factor96,109. Inhibiting NE from digesting proepthilin 
to epthilin will increase cell growth, reduce both inflammation and neutrophil recruitment109.  
 Lastly, SLPI is believed to have a protective role in lower reproductive tract infections. 
Lower levels of SLPI in the reproductive tract is thought to increase susceptibility to infection110. 
One study found decreased SLPI levels in vaginal secretions of women with lower reproductive 
tract infections110. SLPI may also be decreased in pregnant women with asymptomatic 
trichomoniasis9. As previously mentioned, SLPI demonstrates antimicrobial activity against 
Candida albicans, Neisseria gonorrhoeae and HIV to prevent infection50.   
 Seeing that SLPI plays a role in lower reproductive tract infection, we questioned 






in knowledge. To investigate this we use a 129;BL/6 SLPItm1Smw/J (Slpi-/-) mice and a well 
established model of UTI that strongly parallels disease in humans111. C57BL/6 mice robustly 
exfoliate bladder epithelial cells in response to UTI and can therefore clear bacteriuria within 7-
10 days9,24,112. More than half of these mice will clear bacteria in the urine within 48 hpi, 
however, they are still susceptible to rUTI possibly through QIR formation8,9,112. To combat 














Figure 1.3 Proposed mechanisms of SLPI in UTI 
 
A. The antiprotease function of SLPI could inhibit serine proteases secreted by activated 
neutrophils including neutrophil elastase (NE) and cathepsin G. SLPI may also be found 
decorated on NETs following NETosis. Alternatively, SLPI may act against serine 






B. As an antimicrobial protein, SLPI may exhibit bactericidal effects on invading UPEC 
though binding of surface molecules to inhibit adherence to the epithelium. SLPI may act 
against molecular molecules secreted by UPEC. Additionally, SLPI may prevent 
translation of proteins through direct binding of DNA and mRNA.  
C. SLPI also demonstrated anti-inflammatory effects. This may be achieved through 
inhibition of the NFκB pathway which promotes inflammation through transcription of 
pro-inflammtory cytokines. Some evidence suggests it may tranlocate to the nucleus and 
directly bind promoter sites for NFκB genes. SLPI may also inhibit recruitment of 





















































Urinary tract infections (UTIs) affect approximately 150 million people per year 
worldwide1,2. One year in the United States alone sees 10 million outpatient and emergency 
room visits with over 3 billion dollars spent toward sick leave and treatment of these patients, the 
majority of whom are women1–4. Women are at higher risk of developing a UTI due to length 
and proximity of the urethra to other orifices where bacteria are abundant5,6. More than 50% of 
women will experience a UTI in their lifetime, of which 25% are likely to suffer from a second 
infection within 6 months and risk causing future recurrent infections7–9. 
         Uropathogenic Escherichia coli (UPEC) causes more than 75% of community-acquired 
and 50% of nosocomial infections1,14. Although commensal to the gut microbiome, these species 
become pathogenic in the urinary tract16. In a mouse model of UTI, UPEC upregulates 
production of proteases and cellular adhesion molecules, including type I pili, to aid epithelial 
cell invasion16,17. While protected from host defenses inside the cell, bacteria rapidly expand 
replication to form intracellular bacterial communities (IBCs). Some infected cells undergo 
exfoliation and apoptosis, resulting in cell contents being spilled into the urine9,23. 
         Due to the increasing number of multidrug resistance genes found in UPEC strains, 
accurate diagnosis of a UTI is crucial2,113. Currently, clinical diagnosis of a UTI uses an 
antiquated method of culturing bacteria from clean-catch urine specimens and applies a cutoff of 
105 colony forming units per milliliter (CFU/ml) to label a culture as positive103. However, in 
cases of asymptomatic bacteriuria, patients return a positive culture in the absence of UTI 
symptoms40. Furthermore, E. coli is the species most frequently isolated from these patients and 
therefore significantly complicates distinguishing a UTI from other conditions40,41. Recently, use 






provided evidence of a urinary microbiome in healthy people, challenging the belief that urine is 
sterile27,44. In addition to culturing, urinalysis can help diagnose infection, but has a high false 
positive rate25. Development of other biomarkers of UTI may assist in distinguishing a current 
infection from other conditions.   
In response to a UTI, the host increases production of antimicrobial peptides (AMPs) as 
part of the innate immune response49. These molecules, often small, cationic proteins, serve to 
fight invading pathogens. One AMP, secretory leukocyte protease inhibitor (SLPI), is known to 
be expressed by mucosal tissues, namely epithelial cells, and secreted into fluids50,66. Some 
evidence shows SLPI is expressed in the bladder and excreted in urine, but has not been well 
characterized for its role in urinary tract infection57,66,67. SLPI responds to LPS and demonstrates 
specific bactericidal activity against E. coli in vitro69,92. Additionally, reduced levels of SLPI in 
vaginal secretions of women with lower reproductive infections supports the idea that it is 
protective in this region110. Indeed, SLPI can bind Neisseria gonorrhoeae and Candida albicans 
to prevent invasion of host epithelial cells77,78. Along with antimicrobial activity, SLPI also 
possesses antiprotease and anti-inflammatory functions the latter of which are attributed to 
inhibition of the NFκB pathway from transcribing pro-inflammatory cytokines including 
TNFα90. 
In this study, we inoculated wild-type (WT) and slpi knock out (Slpi-/-) mice with UPEC 
to investigate the role of SLPI in urinary tract infection. To determine whether it may be a useful 
biomarker for the diagnosis of UTI, we characterized the production of SLPI during infection 








2.2.1 Mouse model of UTI with UTI89-KanR 
To study the effect of SLPI in vivo, we used 129;BL/6 SLPItm1Smw/J mice which contain a 
nucleotide insertion that terminates SLPI gene expression96. Mice were backcrossed to C57BL/6J 
mice for 9 generations and homozygous breeding was used to produce WT and Slpi-/- mice for 
experiments. Homozygous breeding was used to optimize experimental groups since Slpi-/- mice 
tend to have infrequent litters with fewer pups surviving to weaning age compared to littermate 
WT mice (data not shown). Originally, the Slpi-/- model was developed to characterize the roles 
of this protein in wound healing, but have also been used to explore the role of SLPI in immune 
tolerance and parasitic infection79,96,114.  
 We used an established model of mouse urinary tract infection to investigate the role of 
SLPI in the urinary tract (Figure 2.1). Briefly, we grew UTI89-KanR, originally a UPEC clinical 
isolate, under static conditions to induce expression of type I pili on the bacterial surface18. This 
structure binds mannosides expressed on bladder epithelial cells and is crucial for efficient 
colonization of the bladder and kidney42,115. This strain has been modified to contain a 
kanamycin resistance gene on the bacterial chromosome56. Prior to inoculation, UTI89-KanR was 
resuspended in sterile 1X PBS at a concentration sufficient to deliver 107-108 CFU to the 
bladder9. A higher concentration inoculum is often used in C57BL/6 mice due to their robust 
exfoliation response and therefore fast clearance of bacteriuria compared to C3H/HeN mice, 
which are also commonly used to study UTI9. Urine was collected before transurethral 
inoculation of female mice and also at 3, 7, 12, 24 and 48 hours post infection (hpi). As part of 






invasion68. To investigate the roles of SLPI in the early response to UPEC, we included multiple 
time points for urine collection within a few hours of infection. Submandibular bleed was also 
performed on a subset of mice in which urine was collected prior to bleeding and also before 
bladder inoculation. At 12, 24 or 48 hpi, mice were euthanized by isoflurane overdose and 
bilateral thoracotomy before harvesting blood, bladder and kidney.  
2.2.2. Increased bacterial burden in urinary tracts of Slpi-/- mice  
Previous groups show SLPI has direct antimicrobial properties with specific bactericidal 
activity against E. coli in vitro50,69. To test whether this was the case in vivo, we infected mice as 
described and plated sample dilution series on LB supplemented with kanamycin to select for 
UTI89-KanR. Plates were incubated overnight and CFU/ml or g were calculated the following 
day. In urine, we found Slpi-/- mice tended to have higher UTI89-KanR titers than WT overall 
with the 24 hpi timepoint showing a 10-fold higher titer in Slpi-/- mice compared to WT 
(p=0.002; Figure 2.2A). Although Slpi-/- mice tended to have higher titers overall, there were no 
significant differences found at other time points in the urine. Notably, two WT mice had urine 
counts below the limit of detection (LOD) at 48 hpi. We also saw that Slpi-/- mice had a trend 
towards higher UTI89-KanR titers in bladder tissue at 24 (p=0.06) and 48 hpi (p=0.08, Figure 
2.2B). At 24 hpi, Slpi-/- mice also had higher UTI89-KanR titers than WT in the kidneys although 
a majority of samples from each genotype were below the LOD (p=0.02, Figure 2.2C). These 
data show Slpi-/- mice tend to have higher amounts of bacteria in the urinary tract thereby 






2.2.3 UTI leads to prolonged elevation of SLPI in urine of WT mice 
Previous data showing upregulation of the slpi gene in the bladder suggested that SLPI 
protein may be increased as well as a result of UTI57. However, given that UTI89-KanR titers in 
the urine were increased in Slpi-/- mice and knowing SLPI is normally a secreted protein, we 
thought to first examine urine for changes in SLPI concentration throughout infection. To 
investigate this, we measured SLPI in urine samples collected before and after infection in our 
WT mice (Figure 2.3). We found that prior to infection, all mice had low basal levels of SLPI in 
their urine. Strikingly, starting as early as 3 hpi, we observed a marked increase in urine SLPI in 
mice infected with UTI89-KanR.  Urine SLPI levels peaked at 3 hpi then gradually decreased 
over the course of infection out to 48 hours, with all timepoints remaining above baseline on 
average. This result demonstrates that a UTI results in rapid upregulation of SLPI which remains 
elevated up to two days following infection.   
2.2.4 Bacterial load and SLPI are positively correlated in urine past 12 hpi 
SLPI is upregulated in the presence of bacteria and bacterial products like LPS57,92. In 
this study, we have demonstrated that bacterial titers and SLPI concentration change in the urine 
during a UTI. We asked whether this increase in SLPI was related to the amount of bacteria 
present in the urine. Spearman’s rank correlation coefficient was used to test these two variables 
and showed no correlation at time points before 12 hpi  (p = 0.61, rho = -0.14) (Figure 2.4A). 
However, 12, 24 and 48 hpi, we found that the concentration of SLPI and UTI89-KanR titers in 
the urine are positively correlated (p = 1.76x10-8, rho = 0.73) (Figure 2.4B). These data suggest 
that after 12 hours, the amount of SLPI found in urine is closely associated with the amount of 






2.2.5 SLPI concentration predicts infection in WT urine 
Upon discovering that SLPI concentration is linked to the amount of bacteria present in 
the urine, we asked whether SLPI concentration could be used to predict if a WT mouse has an 
infection. To test this idea, we generated a receiver operating characteristic (ROC) curve which 
tests different classification thresholds to distinguish a true positive (TP) from a false positive 
(FP). The rate of TP and FP is plotted as a line and the area under the curve (AUC) is calculated 
as a range from 0-1. The AUC represents the performance of all thresholds with values closer to 
1 meaning the variable being tested is more likely to be a “perfect” classifier. Using this method, 
we show that SLPI concentrations successfully distinguish infected from uninfected urine 
samples (AUC = 0.91) (Figure 2.5). Additionally, the optimal threshold can be extracted from 
the ROC curve analysis to visualize how samples were classified. In this case, our analysis found 
this value to be 1.07 ng/ml of SLPI (Figure 2.4 dashed line). Using this threshold, more than 
80% of samples were classified correctly as infected or uninfected (uninfected = 25, infected = 
44; Figure 2.5 inset). Taken together, these data show that SLPI concentration can be used to 
distinguish infected versus uninfected urine samples from WT mice.  
2.2.6 Recombinant human SLPI inhibits UTI89-KanR secreted proteases 
SLPI has been extensively studied for its inhibitory effects on serine proteases produced 
by host cells including neutrophil elastase (NE), cathepsin G, and chymase50. Secretion of NE 
from recruited neutrophils is increased in the lung during airway inflammation and is inhibited 
by SLPI116. During an infection, bacteria like UPEC are also known to secrete proteases16. UPEC 
strains produce and secrete serine proteases like SPATE and Pic/PicU to aid in tissue 






investigate whether recombinant human SLPI (rSLPI) has the capability to inhibit UPEC 
proteases by incubating rSLPI with supernatant from UTI89-KanR culture in presence of casein, 
a substrate for proteases. Protease activity of UTI89-KanR supernatant samples were measured 
with the addition of 5, 0.5 and 0.05 ug/ml of rSLPI (Figure 2.6). Results showed a dose-
dependent decrease in protease activity within 15 minutes of incubation. This data provides 
evidence for the first time that rSLPI may also inhibit bacterial proteases during a urinary tract 
infection.  
2.2.7 TNFα trends higher in infected Slpi-/- bladder 
Previous studies that have investigated the role of SLPI in modulating inflammation in 
mouse models of asthma and colitis have shown increased levels of TNFα in Slpi-/- mice91,95. 
This finding is attributed to the ability of SLPI to inhibit activation of the NFκB pathway to 
reduce local inflammation90,91,95. An in vitro study found mast cells secrete TNFα that can then 
activate NFκB in urothelial cells62. This pathway is also activated during a urinary tract infection 
in response to LPS to upregulate expression of inflammatory cytokines including TNFα58,118. We 
tested whether this finding would hold true in our mouse model of UTI by measuring the amount 
of TNFα in homogenized bladder tissue from Slpi-/- and WT mice (Figure 2.7). We saw Slpi-/- 
mice tended to have higher levels of TNFα compared to WT. In congruence with previous 
findings, this data shows that Slpi-/- mice have increased inflammation during UTI perhaps due to 








SLPI is known to be expressed on mucosal surfaces including the respiratory, intestinal 
and urogenital tracts50,67. The role of SLPI in airway inflammation and wound healing is well 
studied, but only one group has addressed the regulation of SLPI in response to UTI using a 
spinal cord injury model in rats50,57. After 24 hours of UPEC infection, sham rats had higher 
amounts of slpi transcripts in bladder tissue compared to injured rats57. This data suggests that 
SLPI may be involved in innate immune response to bacterial insult, but the specific role of SLPI 
in urinary tract infection has not yet been described.  
To fill this gap in knowledge, we used a Slpi-/- mouse model to better understand the role 
SLPI plays in the host response to UTI. First, we inoculated mice with UTI89-KanR and found 
that Slpi-/- mice tended to have increased bacterial titers in the urine, bladder and kidney 
compared to WT (Figure 2.2). This trend held true for most of the collected time points, however 
we observed the strongest difference at 24 hpi. This timepoint seems to be important in other 
human, mouse and cell culture models examining the role of SLPI as well57,119–121. This may be 
attributed to a rapid increase in SLPI early on that declines as other members of the immune 
system come into play.  
In WT mice, high SLPI concentrations in early time points supports our hypothesis that 
there is a rapid increase in SLPI. In fact, we saw an approximate 8 fold increase just 3 hours after 
bladder inoculation that gradually declined over time (Figure 2.3). As part of the innate immune 
system, it is not surprising that SLPI levels increased quickly49,68. A similar finding has been 
shown for cathelicidin, another AMP found in urine. In vitro infection of bladder epithelial cells 
with UTI89 revealed increased cathelicidin transcripts that peaked just 5 minutes after infection 






innate immune signaling, our data suggests that SLPI is quickly produced or secreted in large 
quantities to respond to bacterial insult. We hypothesize that transcription of SLPI decreases as 
other host defenses are activated to take control of the infection. Previous research shows that 
inflammatory cytokines that signal recruitment of immune cells are upregulated within 1 hour of 
infection in the urinary tract48,58. Within 2 hpi, neutrophils arrive in the lumen of the infected 
bladder and peak in abundance at 6 hpi59,60. Furthermore, we show UTI89-KanR titers and SLPI 
concentration are correlated in the urine at 12, 24 and 48 hpi, but not at earlier time points 
(Figure 2.4). Taken together, our data suggests that the concentration of SLPI before 12 hours is 
not proportional to the severity of infection. It’s possible that interactions taking place between 
SLPI, pro-inflammatory cytokines and immune cells within the first few hours of infection will 
still affect the immune response after 12 hpi and may in part explain the difference in bacterial 
burden at 24 hpi.  
SLPI is known to have antimicrobial, antiprotease and anti-inflammatory properties and 
could therefore contribute to fighting UTI in multiple ways50. In vitro assays demonstrate SLPI 
to have bactericidal effects against gram negative bacteria including E. coli69. Additionally, SLPI 
binds LPS and CD14 thereby preventing LPS-CD14 complexes from forming and being taken up 
by macrophages in cell culture118. This implies SLPI may also directly bind bacteria. Or, like 
other cationic AMPs, SLPI could be killing UTI89 by destabilizing its membrane49,55. Yet 
another way SLPI may inhibit bacterial function is through its interaction with nucleic acids. 
SLPI has the potential to block protein synthesis by binding negatively charged mRNA and DNA 
in a cell free system14. Such a mechanism would be dependent on the ability of SLPI to enter 
bacterial cells which has not yet been shown. However, an observation we made while 






cultures even before IPTG induction (data not shown). This implies that SLPI expressed inside a 
bacterial cell can still carry out bactericidal activity. We have since adapted our protocol to 
include a plasmid containing GST-fusion to dampen the antimicrobial activity of SLPI which 
appears to have resolved the growth inhibition we observed when expressing SLPI alone (data 
not shown). A future direction we plan to pursue is to create a transposon library of mutant 
UTI89 and culture it with and without rSLPI to identify specific bacterial genes targeted by SLPI 
antimicrobial activity.  
Another mechanism SLPI may employ to defend the host is through inhibition of 
proteases. Many groups have studied the ability of SLPI to directly inhibit neutrophil elastase 
(NE) in lung inflammation50,75. Once recruited to the site of inflammation, neutrophils release 
non-specific proteases like NE that increase inflammation50. However, NE can also attack host 
tissue to cause damage and in excess, actually slows the healing rate of tissue as shown in a 
mouse model of chronic wounds96. To combat this detrimental effect on the host, neutrophils 
synthesize and release SLPI at the same time50. This restores balance to the inflammatory 
environment and keeps host tissue damage under control. Therefore, Slpi-/- mice may have more  
inflammation in part due to reduced inhibition of host proteases like NE. In addition to its effects 
on endogenous proteases, we show that SLPI may also inhibit bacterial proteases (Figure 2.6). 
UPEC strains secrete serine proteases that weaken host tissue117. Some of these proteases are 
important for colonization and invasion of epithelial cells122. In this study, we show that rSLPI 
inhibits bacterial proteases secreted by UTI89-KanR in a dose dependent manner. This evidence 
suggests that SLPI may also act directly against bacterial proteases, which would suggest another 






In addition to these functions, SLPI also possesses anti-inflammatory properties that may 
be involved in fighting urinary tract infection. SLPI modulates inflammation by reducing LPS 
activation of TLR4 and therefore downregulating transcription of NFκB pro-inflammatory genes 
including TNFα90,118. This may be achieved by preventing activation of IkBβ, the molecule that 
translocates to the nucleus to transcribe genes, or by competitive binding of SLPI to DNA in the 
nucleus to prevent transcription90. We show Slpi-/- mice tend to have increased levels of TNFα in 
bladder tissue at 24 hpi, although this effect may be due to the anti-inflammatory effects of SLPI 
or worsened UTI severity (Figure 2.7). While this is consistent with previous findings, further 
investigation of other inflammatory markers is needed to better understand if and how SLPI 
modulates inflammation in the urinary tract.  
In our mouse model of UTI, increased SLPI in the urine is positively correlated to the 
amount of bacteria present starting at 12 hpi. We questioned whether SLPI could be used as a 
biomarker of UTI as current methods of diagnosis are under scrutiny in the scientific 
community25,27. Not only is the gold standard culturing technique limited in selectivity, but ABU 
and evidence of a urinary microbiome can lead to false positive results and subsequent 
unnecessary antibiotic treatment. To investigate if SLPI would be a good candidate, we used a 
receiver operating characteristic (ROC) curve to show that SLPI measured in urine can 
distinguish infected and uninfected samples with a high level of accuracy with the model 
correctly classifying 80% of samples (Figure 2.5 inset). This model performs better at early time 
points of UTI likely due to the flood of SLPI produced within the first few hours. After 12 hpi, 
bacteria begin to clear and SLPI levels decrease. At 48 hpi, two mice had bacterial titers below 
the LOD which is expected in C57BL/6 mice as a result of their rapid clearance of bacteriuria8,9. 






to classify the mice that have titers below the LOD even though they still have bacteria in the 
bladder (Figure 2.5). However, the bacteria in the bladders of these mice could be mostly 
intracellular at this time period. More experiments including a long term UTI would help to 
clarify this observation. 
One question we are still addressing is where SLPI comes from in a mouse model of UTI. 
SLPI is synthesized and secreted by multiple cell types including epithelial cells and 
macrophages in response to cytokine and LPS stimuli respectively92,108. Neutrophils are also a 
major source of SLPI and release it into the extracellular environment when activated89. Our 
findings imply that SLPI is likely produced by epithelial cells since a large quantity of SLPI is 
already present in the urine at 3 hpi and is unlikely to originate solely from recruited cells. 
However, this does not completely rule out the possibility that resident macrophages could be 
significantly contributing to this production and although neutrophils are shown to be most 
abundant at 6 hpi, it’s possible they may contribute to urine SLPI levels very early in UTI.  
One way in which we attempted to answer this question was to compare serum levels 
of  SLPI before UTI and 24 hpi. We took submandibular bleeds before infecting mice and 
collected urine before each manipulation. Serum levels of SLPI in these mice did not seem to 
change significantly over the 24 hour infection (data not shown), however we discovered all time 
points after submandibular bleed had increased levels of SLPI in the urine (Supplemental Figure 
2.1). We saw increased levels of SLPI in urine collected right before bladder inoculation (0 hpi), 
compared to urine before the submandibular bleed (-2 hpi) which closely resembled baseline 
from other experiments. While this increase in SLPI following submandibular bleed was 
unexpected, we hypothesize this excess SLPI is produced at the mandible to aid in wound 






injection of SLPI in rats, dogs and humans has resulted in high levels of SLPI in the urine67,123. 
Serum SLPI levels also increase during infection67. Taken together, these findings suggest that 
exceeding the homeostatic level of SLPI in the blood leads to excretion of SLPI in the urine. In 
our model, a better way to investigate where SLPI is coming from is to perform flow cytometry 
on infected bladder tissue. This will inform us what cells are recruited to the site of infection at 
specific timepoints. Based on those experiments, we plan to use a mouse cre/LoxP system to 
knock out SLPI in one cell type to reveal its contribution during a UTI. Currently, we plan to 
examine this by breeding albumin-cre, to diminish SLPI from circulating immune cells, and 
uroplakin-cre, to knock out SLPI in the bladder epithelium.  
One limitation of this current study is that the mice we used are incompletely 
backcrossed. Mice arrived to us as a mixed background 129 and C57BL/6J and we are in the 
process of fully backcrossing them to a BL/6 background. Mice with mixed backgrounds can 
have phenotypic differences from fully backcrossed versions and be a source of variability124. 
Traditionally, a fully backcrossed mouse is one that has been bred to the desired background for 
a minimum of 10 generations (N10)125. For these experiments, we used N5 generation mice with 
the intention of confirming our findings with N9 and N10 mice at a later date. So far, we have 
not seen any noticeable differences between the two generations, but experiments with fully 
backcrossed mice will be done to confirm our findings. We also hope to use heterozygous 
breeding with WT littermate controls in future experiments as well, however the viability of  
Slpi-/- mice we observed will make this challenging.  
Another limitation of the current study is the lack of translation to humans. Thus far, we 
have successfully shown SLPI to be important in a mouse model of UTI, but this has yet to be 






SLPI inhibits the activity proteases secreted by UTI89-KanR (Figure 2.6). Additionally, ongoing 
experiments using 5637 cells, an immortalized human bladder cell line, provide evidence that 
SLPI is secreted by bladder epithelial cells in response to infection with UTI89-KanR (data not 
shown). To unambiguously show that SLPI is upregulated during urinary tract infection in 
humans, we plan to measure and compare SLPI levels in urine samples from patients with and 
without UTI. These experiments will be used to guide future directions with the goal of 
developing a biomarker of urinary tract infection to reduce misdiagnosis and prevent further 
evolution of multidrug resistant bacteria.  
 In conclusion, we demonstrate in this study that SLPI plays a protective role in urinary 
tract infection to reduce bacterial burden. Urine SLPI levels increase rapidly within the first few 
hours of infection and remain elevated up to 48 hours afterward. In addition to antimicrobial 
properties, this protein may also utilize antiprotease and anti-inflammatory properties to control 
infection and reduce inflammation in the bladder. We propose that SLPI levels can also be used 
to predict infection in a mouse model and may prove to be a biomarker of UTI in humans. 
Further investigation into human urinary tract infection is needed to evaluate the translation of 











2.4 Materials and Methods 
Mice 
All animal procedures were reviewed by the Washington University Institutional Animal Care 
and Use Committee (Protocol#: 20180286). Cryo-recovered 129;BL/6 SLPItm1Smw/J mice 
(Jackson Laboratories Bar Harbor, ME) were backcrossed to WT BL/6 mice for 9 generations. 
Mice used in this study were from the 5th and 9th generations.   
Bacterial Strains and Cultivation 
A kanamycin-resistant derivative of a human cystitis isolate, UTI89: UTI89-KanR provided by 
Scott J Hultgren was used to infect mouse bladders.  
Mouse Infection 
Bacterial cultures were started from a single colony in 20 ml of Luria-Bertani broth (LB) and 
grown statically at 37C overnight, subcultured 1:1000 into 20 ml of sterile LB and grown 
statically at 37C for 18-24 hours. Bacteria were spun down (3,000rpm for 15 min) and 
resuspended in sterile 1X PBS. Inoculum was diluted to a final concentration of 1-2x109 colony 
forming units (cfu)/ml (1:10 OD600=0.25-0.28) and 50 ul (~0.5-1x10
8cfu) was used to inoculate 
the bladders of 6-7 week old female mice by transurethral catheterization under 2.5% isoflurane.  
Urine Collection and Bacterial Titering 
Urine was collected at 0, 3, 7, 12, 24 and 48 hours post infection by applying suprapubic 






serially diluted 1:10 in sterile PBS and 5 ul of each dilution was spotted onto LB agar 
supplemented with 50 ug/ml kanamycin (LB/Kan50) five times. Colony counts were averaged 
for the highest dilution containing colonies in 4 or more replicates and CFU/ml was calculated. 
Remaining urine sample was frozen at -80C.   
Tissue Bacterial Titering 
Bladder and kidneys were aseptically harvested into pre-weighed tubes containing 1 ml of sterile 
PBS. Final weights were measured then samples were homogenized. Samples were serially 
diluted 1:100 in sterile PBS and titered as described above to calculated CFU/g of tissue.  
Protein Quantification by ELISA 
Urine samples were thawed and diluted 1:10 (pre-infected) or 1:20 (infected) in 1XPBS + 1% 
BSA. SLPI was measured using Mouse SLPI DuoSet ELISA (R&D Systems DY1735-05) 
according to manufacturer’s instructions.  
Homogenized bladder tissue was spun down (10,000rpm, 5 min) and supernatant was transferred 
to a 0.22 um SpinX column (Costar CS8160) to remove bacteria. Filtered samples were saved at 
-20C until use. TNFα was measured by ELISA (BioLegend 430901) on undiluted samples 
following manufacturer’s instructions.  
 
Protease activity 
UTI89-KanR was grown under conditions previously explained. Culture was spun down 






residual bacteria. Protease activity was measured on supernatant samples using the Pierce 
























Figure 2.1: Schematic of UTI mouse model 
Transurethral inoculation of 6-7 week old female WT and Slpi-/- mice with 107-108 CFU of 











Figure 2.2: Increased bacterial burden in urinary tract of Slpi-/- mice 
A. Urine was collected at 3, 7, 12, 24 and 48 hpi and titers determined  
B. Mice were sacrificed and harvested. Bladder and kidney were homogenized and plated 
for titers at 12, 24 and 48 hpi (B and C).  
Shape denotes number of backcrosses to C57BL/6 background.  
Dashed line represents the limit of detection for that specimen. 
Statistical significance: one-tailed Wilcoxon rank-sum test, boxes indicate 25th and 75th 























Figure 2.3: UTI leads to prolonged elevation of SLPI in urine of WT mice 
ELISA quantification of SLPI in urine from before and after infection of WT mice.  
Dashed line indicates optimal threshold (1.07 ng/ml) determined in Fig2.5. 
Statistical significance: two-tailed Wilcoxon rank-sum test, boxes indicate 25th and 75th 






















Figure 2.4: Bacterial load and SLPI are correlated after 12 hpi 
A. Correlation between SLPI and UTI89-KanR present in the urine at 3 and 7 hpi. 
B. Correlation between SLPI and UTI89-KanR present in the urine at 12, 24 and 48 hpi. 
Dashed line indicates limit of detection for that specimen. 


































Figure 2.5: Urine SLPI concentration predicts infection in WT mice 
Receiver operating characteristic (ROC) curve analysis of SLPI levels in urine to test to classify 





























Figure 2.6: Recombinant human SLPI inhibits UTI89-KanR secreted proteases 
UTI89KanR grown for 2 x 24 hours under type I inducing conditions was centrifuged. The 
supernatant was filtered and incubated in presence of 5, 0.5, 0.05 µg/ml rSLPI for 15 minutes. A 






















Figure 2.7: Increased levels of TNFα in Slpi-/- mice with UTI 
ELISA analysis of TNFα concentration in homogenized bladder tissue from WT and Slpi-/- mice. 
Statistical significance: one-tailed Wilcoxon rank-sum test, boxes indicate 25th and 75th 


















Supplemental Figure 2.1: Submandibular bleed increases SLPI levels in urine of WT mice 
Submandibular bleed of mice was taken 2 hours prior to transurethral inoculation of the bladder. 
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